Clinical data on treatment regimen and use of medication among patients with hemophilia B in Korea
Authors:
Open Access
- 8 August 2024
- journal article
- research article
- Published by Springer Nature in Blood Research
- Vol. 59 (1) , 1-7
Abstract
Background: To investigate the clinical treatment status, such as treatment regimen, bleeding events, and drug dose, in patients with hemophilia B in South Korea. Methods: In this retrospective chart review, data of patients with hemophilia B from eight university hospitals were collected. Demographic and clinical data, treatment data, such as regimen and number of injections, dose of factor IX concentrate, and bleeding data were reviewed. Descriptive analyses were performed with annual data for 2019, 2020, and 2021, as well as the three years consecutively. Results: The medical records of 150 patients with hemophilia B between January 1, 2019, and December 31, 2021, were collected. Among these, 72 (48.0%) were severe, 47 (31.3%) were moderate, and 28 (18.7%) were mild. The results showed approximately two times more patients receiving prophylaxis as those receiving on-demand therapy, with 66.1% of patients receiving prophylaxis in 2019, 64.9% in 2020, and 72.1% in 2021. Annualized bleeding rates were 2.2% (± 3.1) in 2019, 1.8% (± 3.0) in 2020, and 1.8% (± 2.9) in 2021 among patients receiving prophylaxis. For the doses of factor IX concentrate, patients receiving prophylaxis received an average of 41.6 (± 11.9) IU/Kg/Injection in 2019, 45.7 (± 12.9) IU/Kg/Injection in 2020, and 60.1 (± 24.0) IU/Kg/Injection in 2021. Conclusions: Clinically, prophylaxis is more prevalent than reported. Based on insights gained from current clinical evidence, it is expected that the unmet medical needs of patients can be identified, and physicians can evaluate the status of patients and actively manage hemophilia B using more effective treatment strategies.Keywords
All Related Versions
Funding Information
- CSL Behring
This publication has 13 references indexed in Scilit:
- An Analysis of Policy Implementation Factors of the School Farm Program in Seoul, South KoreaThe Korea Association of Yeolin Education, 2021
- Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveysOrphanet Journal of Rare Diseases, 2021
- Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world settingAnnals of Hematology, 2020
- WFH Guidelines for the Management of Hemophilia, 3rd editionHaemophilia, 2020
- Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International AnalysisAdvances in Therapy, 2020
- Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor ConcentratesBlood, 2018
- European retrospective study of real‐life haemophilia treatmentHaemophilia, 2016
- The current status of prophylactic replacement therapy in children and adults with haemophiliaBritish Journal of Haematology, 2015
- Future of coagulation factor replacement therapyJournal of Thrombosis and Haemostasis, 2013
- Treatment of Bleeding in HemophiliaJournal of the Korean Medical Association, 2007